Roberto Bianchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roberto Bianchi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Marco Guzzo
Maxillo-Facial Surgery Unit, Otolaryngology and Head and Neck Surgery Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
5 shared publications Jan Godzinski
Medical University of Wroclaw
2 shared publicationsMarco Guzzo
National Cancer Institute
2 shared publications- Nicola Alessandro Iacovelli
Radiotherapy Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
2 shared publications - Sarah Colombo
Maxillo-Facial Surgery Unit, Otolaryngology and Head and Neck Surgery Department, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy
2 shared publications - Alice Indini
Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
1 shared publication
Latest Publications
- Open Access
Mucosal Melanoma of the Head and Neck: A 45-Year Experience of a Tertiary Cancer Center
Background/Objectives. Head and neck mucosal melanoma (HNMM) is a rare, aggressive malignancy with poor outcomes and limited evidence to guide prognostication and treatment. A detailed assessment of long-term survival and prognostic factors is needed to inform clinical management and staging. This work aimed to describe outcomes and prognostic factors in HNMM patients treated over 45 years. Methods. This was a retrospective observational cohort study of consecutive patients treated at a tertiary referral center in Italy from 1975 to 2020. Random-forest-based screening informed covariate selection for Cox models. Endpoints were overall survival (OS), disease-free survival (DFS), and post-recurrence DFS (prDFS). Associations with clinical and pathological variables were evaluated using Kaplan–Meier estimates, log-rank tests, and multivariable Cox regression. Results. Among 112 patients (median follow-up, 121.1 months), 3-/5-year OS was 42.8%/28.0%, DFS 20.5%/13.2%, and 1-/3-year prDFS 36.7%/10.9%. Ulceration was associated with worse OS (HR 2.12; 95% CI 1.05–4.26) and DFS (HR 2.23; 95% CI 1.16–4.28). Male sex showed a trend toward poorer OS and DFS. Regional lymph-node treatment correlated strongly with OS and prDFS (overall p < 0.001), with neck dissection indicating unfavorable risk (OS HR 5.22; 95% CI 2.39–11.40). Conclusions. HNMM remains a high-mortality disease with frequent recurrence. Ulceration and nodal involvement were key adverse prognostic factors, while surgery was associated with improved survival. The findings support incorporating ulceration into future staging and highlight the potential for durable control through salvage surgery. Further investigation of treatment intensification, biomarkers, and multimodal strategies is warranted.
Open AccessMucosal Melanoma of the Head and Neck: A 45-Year Experience of a Tertiary Cancer Center
Background/Objectives. Head and neck mucosal melanoma (HNMM) is a rare, aggressive malignancy with poor outcomes and limited evidence to guide prognostication and treatment. A detailed assessment of long-term survival and prognostic factors is needed to inform clinical management and staging. This work aimed to describe outcomes and prognostic factors in HNMM patients treated over 45 years. Methods. This was a retrospective observational cohort study of consecutive patients treated at a tertiary referral center in Italy from 1975 to 2020. Random-forest-based screening informed covariate selection for Cox models. Endpoints were overall survival (OS), disease-free survival (DFS), and post-recurrence DFS (prDFS). Associations with clinical and pathological variables were evaluated using Kaplan–Meier estimates, log-rank tests, and multivariable Cox regression. Results. Among 112 patients (median follow-up, 121.1 months), 3-/5-year OS was 42.8%/28.0%, DFS 20.5%/13.2%, and 1-/3-year prDFS 36.7%/10.9%. Ulceration was associated with worse OS (HR 2.12; 95% CI 1.05–4.26) and DFS (HR 2.23; 95% CI 1.16–4.28). Male sex showed a trend toward poorer OS and DFS. Regional lymph-node treatment correlated strongly with OS and prDFS (overall p < 0.001), with neck dissection indicating unfavorable risk (OS HR 5.22; 95% CI 2.39–11.40). Conclusions. HNMM remains a high-mortality disease with frequent recurrence. Ulceration and nodal involvement were key adverse prognostic factors, while surgery was associated with improved survival. The findings support incorporating ulceration into future staging and highlight the potential for durable control through salvage surgery. Further investigation of treatment intensification, biomarkers, and multimodal strategies is warranted.
- 30 May 2025
- Published by Elsevier in Oral Oncology
- Vol. 167, 107405
Mandibular swing approach: 25 years of experience at Istituto Nazionale Tumori of Milan
- 30 May 2025
- Published by Elsevier in Oral Oncology
- Vol. 167, 107405
Mandibular swing approach: 25 years of experience at Istituto Nazionale Tumori of Milan
- 24 April 2022
- Published by Springer Nature
- p. 127-133
Laryngeal Tumors
- 24 April 2022
- Published by Springer Nature
- p. 113-117
Odontogenic Tumors
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6049
Activity of afatinib administered in a window pre-operative study in squamous cell carcinoma of the head and neck (SCCHN) : EORTC-90111.
6049 Background: Targeted agents (TA) are often investigated in unselected end-stage cancer patients (pts), making difficult to fully evaluate their activity and impairing translational research. One way to resolve this issue is to perform "window" studies where a TA is given between the diagnosis and surgery. Afatinib (A) is an oral ErbB family blocker that improves PFS of pts with recurrent SCCHN after platinum failure. Methods: This study was a randomized, multicenter, phase II window of opportunity trial. Treatment-naïve SCCHN pts selected for primary curative surgery were randomized (5:1 ratio) to receive A during 14 days (day -15 until day -1) before surgery (day 0) or no treatment (B). Tumour biopsies, FDG/PET, and MRI were performed at diagnosis and at surgery. The primary end point was metabolic FDG-PET/CT response (centrally reviewed; H0 = 10%, H1 = 30%, Alpha = 10% 1-sided, Power = 90%); according to EORTC guidelines). Other endpoints included response by RECIST, DCE MRI, DWI MRI, and translational research. Results: 30 pts were randomized in 4 centers: 25 to A and 5 to B. 23 pts randomized to A were eligible (median age: 59, male/female: 16/7, oral cavity/oropharynx: 19/4; ECOG 0/1: 15/8, stage II/III/IV: 4/4/15). One pt discontinued A after 11 days for gr3 renal failure and diarrhea with delayed surgery by 24 days. Another pt had gr3 acneiform rash. Of the 24 pts who completed the planned A treatment, 2 had delayed surgery by 4 and 2 days (gr2 colitis and organizational issues). No surgical complications were related to A. Of the 23 eligible pts, 16 had a partial metabolic FDG/PET response (PMR): 70% (95% CI: 47-87%). There were no complete responses and 7 pts had stable disease (SMD). The proportion of responders to A was significantly higher than 10% (p < 0.001). There was no CMR/PMR in the no-treatment arm (n = 3). Conclusions: This study demonstrates that multinational challenging window studies are feasible. Preliminary results show that A given for 2 weeks to newly diagnosed SCCHN pts induces a high rate of FDG-PET response and can be safely administered before surgery. Definitive results will be presented at ASCO 2016. Translational research to evaluate predictive biomarkers is ongoing Clinical trial information: NCT01538381.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6049
Activity of afatinib administered in a window pre-operative study in squamous cell carcinoma of the head and neck (SCCHN) : EORTC-90111.
6049 Background: Targeted agents (TA) are often investigated in unselected end-stage cancer patients (pts), making difficult to fully evaluate their activity and impairing translational research. One way to resolve this issue is to perform "window" studies where a TA is given between the diagnosis and surgery. Afatinib (A) is an oral ErbB family blocker that improves PFS of pts with recurrent SCCHN after platinum failure. Methods: This study was a randomized, multicenter, phase II window of opportunity trial. Treatment-naïve SCCHN pts selected for primary curative surgery were randomized (5:1 ratio) to receive A during 14 days (day -15 until day -1) before surgery (day 0) or no treatment (B). Tumour biopsies, FDG/PET, and MRI were performed at diagnosis and at surgery. The primary end point was metabolic FDG-PET/CT response (centrally reviewed; H0 = 10%, H1 = 30%, Alpha = 10% 1-sided, Power = 90%); according to EORTC guidelines). Other endpoints included response by RECIST, DCE MRI, DWI MRI, and translational research. Results: 30 pts were randomized in 4 centers: 25 to A and 5 to B. 23 pts randomized to A were eligible (median age: 59, male/female: 16/7, oral cavity/oropharynx: 19/4; ECOG 0/1: 15/8, stage II/III/IV: 4/4/15). One pt discontinued A after 11 days for gr3 renal failure and diarrhea with delayed surgery by 24 days. Another pt had gr3 acneiform rash. Of the 24 pts who completed the planned A treatment, 2 had delayed surgery by 4 and 2 days (gr2 colitis and organizational issues). No surgical complications were related to A. Of the 23 eligible pts, 16 had a partial metabolic FDG/PET response (PMR): 70% (95% CI: 47-87%). There were no complete responses and 7 pts had stable disease (SMD). The proportion of responders to A was significantly higher than 10% (p < 0.001). There was no CMR/PMR in the no-treatment arm (n = 3). Conclusions: This study demonstrates that multinational challenging window studies are feasible. Preliminary results show that A given for 2 weeks to newly diagnosed SCCHN pts induces a high rate of FDG-PET response and can be safely administered before surgery. Definitive results will be presented at ASCO 2016. Translational research to evaluate predictive biomarkers is ongoing Clinical trial information: NCT01538381.
- 28 October 2011
- Published by Springer Nature
- p. 175-179
Odontogenic Tumors